China BioNanometer (CBIU) Announces Breakthrough Nanotech Oral Flu Prevention Granules

The market in China for nanotechnology products and systems was US$ 5.4 billion in 2005 and will increase to US$ 31.4 Billion by 2010 and US$ 144 Billion by 2015

Many people don't know it yet, but we're in the beginning stages of The Nanotech Revolution

China BioNanometer Industries (CBIU), one of the few profitable nanotech companies in the World, just announced the introduction of two new products using nanotechnology for the prevention and treatment of influenza. One is an "Anti-influenza Oral Granule" and the other is an "Influenza Partner" used to treat the flu. There are probably hundreds of millions of cases of the flu in China each year.

Nanotechnology covers many areas of research dealing with objects that are measured in nanometers. A nanometer is one-billionth of a meter; for comparison a human hair is 80,000 nanometers (nm) thick. China BioNanometer (CBIU) specializes in R & D, production, and the sale of nanometer level pharmaceutical, health food, and cosmetic products. Using nanometer level raw material in cosmetics and pharmaceuticals reduces costs because fewer ingredients are needed to make the end product while substantially increasing the products effectiveness and shelf life.

Currently the Unites States is leading the research in Nanotechnology with China not far behind. The U.S. Government has given the National Nanotechnology Initiative NNI a budget of $ 1.5 Billion for next year, reflecting steady growth in the NNI investment.

http://www.nano.gov/NNI_FY09_budget_summary.pdf

Recently China BioNanometer filed their 10Q Quarterly Report with the S.E.C. for the 2nd Quarter of ’07. They reported an operating profit of $ 1.6 Million from $ 2.5 Million in sales in the first six months of ’07. This is 100% growth year to year over 2006.

China BioNanometer has developed influenza prevention granules that are better than the "Banlangen Granules" currently used at this time. The timing couldn't be better since Good Morning America reported February 23rd that "this year's flu shot seems to not be effective. It doesn't match two of the three main flu bugs knocking people down."

http://www.abcnews.go.com/GMA/ColdFlu/story?id=4334018&page=1  

Normally the vaccine eliminates more than 70% of potential cases, but this year it's about 40%. The flu vaccine currently takes between six and nine months to be made. So when scientists were preparing the coming year's formula they have to guess which strains are going to be dominant months in advance. This year they guessed wrong. According to ABC News "The mistake doesn't just lead to fevers, coughing and sneezing. An estimated 36,000 Americans die each year from influenza."

Currently influenza patients could suffer liver and kidney damage, despite having a flu shot. Scientific studies have proven China BioNanometer's "Anti-influenza Oral Granules" can restore a damaged liver and kidneys.

Although their initial target market is China, export possibilities do exist. This is the first of many new products to come. As this story gets picked up by medical journals within the next few days, you can expect the medical community as well as the investment community to get involved in the stock. With the explosive growth expected in this industry within the next few years, this company is poised to move. Once this company starts gaining exposure within the next few days and weeks, the share price could climb.

There are good reasons to consider this stock, the first is the Chinese Government has made CBIU's technology the Industry Standard for Nanotechnology in China, and secondly they just completed building one of the biggest and most sophisticated nanotechnology factories in China. This "BioNanometer Sci-tech Park" will integrate R & D as well as the production of over 500 million nanometer pharmaceutical tablets, over 3 million pieces of nanometer cosmetics, tons of nanometer powder, and many other products.

Source: China Bionanometer Industries Corporation